Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target?

• Published in: Expert Opinion on Therapeutic Targets
• Main Author: 2-s2.0-85049096441
• Format: Review
• Language: English
• Published: Taylor and Francis Ltd 2018
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049096441&doi=10.1080%2f14728222.2018.1486822&partnerID=40&md5=64f55f1df48cbd095a93ff671a3e32f2

Introduction: Disturbances of extracellular matrix (ECM) homeostasis in trabecular meshwork (TM) cause increased aqueous outflow resistance leading to elevated intraocular pressure (IOP) in glaucomatous eyes. Therefore, restoration of ECM homeostasis is a rational approach to prevent disease progression. Since renin-angiotensin system (RAS) inhibition positively alters ECM homeostasis in cardiovascular pathologies involving pressure and volume overload, it is likely that RAS inhibitors reduce IOP primarily by restoring ECM homeostasis. Areas covered: Current evidence showing the presence of RAS components in ocular tissue and its role in regulating aqueous humor dynamics is briefly summarized. The role of RAS in ECM remodeling is discussed both in terms of its effects on ECM synthesis and its breakdown. The mechanisms of ECM remodeling involving interactions of RAS with transforming growth factor-β, Wnt/β-catenin signaling, bone morphogenic proteins, connective tissue growth factor, and matrix metalloproteinases in ocular tissue are discussed. Expert opinion: Current literature strongly indicates a significant role of RAS in ECM remodeling in TM of hypertensive eyes. Hence, IOP-lowering effect of RAS inhibitors may primarily be attributed to restoration of ECM homeostasis in aqueous outflow pathways rather than its vascular effects. However, the mechanistic targets for RAS inhibitors have much wider distribution and consequences, which remain relatively unexplored in TM. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.